Developer docs
API playgroundTry for free, no card

Search company profiles

Arbutus Biopharma

Full company profile

uuid0003iuj

Namestring
Arbutus Biopharma
Legal namestring
Arbutus Biopharma Corporation
Websiteurl
arbutusbio.com
Company typeenum
Public
Founded yearint
1992
Descriptiontext

Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company developing a combination therapeutic regimen to achieve a functional cure for chronic hepatitis B virus (HBV) infection. The company's pipeline is built around a three-pronged "Suppress, Reduce, Boost" strategy combining nucleos(t)ide analogues with its proprietary assets: imdusiran (AB-729), a subcutaneously-delivered GalNAc-conjugated RNAi therapeutic designed to reduce all HBV viral antigens including HBsAg; and AB-101, an oral small-molecule PD-L1 checkpoint inhibitor intended to reinvigorate the host immune response. Imdusiran received FDA Fast Track designation in April 2026 and has demonstrated functional cure in 46% of Phase 2a patients in the IM-PROVE I trial.

The company monetizes its technology through a mix of licensing royalties, milestone payments, and patent litigation proceeds rather than product sales. Its lipid nanoparticle (LNP) delivery platform — foundational to the first FDA-approved siRNA therapeutic ONPATTRO — is licensed to Genevant Sciences (in which Arbutus holds ~16% equity) and Alnylam Pharmaceuticals. A landmark $2.25 billion global settlement with Moderna in March 2026 ($950M upfront plus up to $1.3B contingent on appellate ruling) and a separate ~$190M settlement with Pfizer/BioNTech validate the LNP patent estate. Arbutus also collaborates with Barinthus Biotherapeutics on the IM-PROVE II combination trial. The company is headquartered in Warminster, Pennsylvania, employs 51–100 people, and operates with a leadership team installed in 2025 (CEO Lindsay Androski, CFO Tuan Nguyen, GC Andrew Sung); Roivant Sciences remains its largest shareholder with two board seats.

Short descriptiontext

Arbutus Biopharma is a clinical-stage biopharmaceutical company developing RNAi and oral PD-L1 combination therapies to achieve a functional cure for chronic hepatitis B, monetizing its GalNAc-siRNA and lipid nanoparticle platforms through licensing, royalties, and patent litigation settlements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWarminster, United States
HQ citystring
Warminster
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNAi therapeutics, hepatitis B treatments, biopharmaceutical development, clinical-stage biotechnology, viral disease therapeutics
Industry2 codes
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Hepatitis B Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing Royalties
TypeLicensing Royalties
Description

Tiered low single-digit royalties on future sales of Genevant products covered by licensed LNP patents. If Genevant sub-licenses, Arbutus receives lesser of 20% of sublicensing revenue or tiered low single-digit royalties. Arbutus owns approximately 16% of Genevant common equity.

financialpost.com
2Settlement Revenue
TypeOne Time License
Description

One-time settlement payments from patent litigation. Q1 2026 estimated license revenue of $178.7M from $950M Moderna settlement (July 2026 payment). Additional $1.3B contingent on appellate ruling. Separate $190M from Pfizer/BioNTech settlement.

stocktitan.net
3ONPATTRO Royalties
TypeLicensing Royalties
Description

Tiered royalty payments on global net sales of ONPATTRO (first FDA-approved application of Arbutus' LNP technology by Alnylam). Arbutus sold royalty interest on future global net sales to OMERS but retains second lower royalty from Acuitas settlement.

arbutusbio.com
4Milestone Payments
TypeLicensing Royalties
Description

Potential milestone payment from Alnylam for a product targeting hepatocellular carcinoma, as referenced in Q4 2025 results.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Arbutus Biopharma is a clinical-stage biopharmaceutical company developing a portfolio of therapeutics to achieve a functional cure for chronic hepatitis B (HBV) infection. The company's lead asset, imdusiran (AB-729), is a subcutaneously delivered GalNAc-conjugated RNA interference (RNAi) therapeutic that reduces HBV viral antigens including HBsAg. Its second clinical asset, AB-101, is an oral small-molecule PD-L1 inhibitor designed to reinvigorate the host immune response. Combination regimens including imdusiran, AB-101, nucleos(t)ide analogues, and immunotherapeutics are being evaluated in Phase 2 clinical trials under the company's three-pronged Suppress, Reduce, Boost approach.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 46% of Phase 2a patients achieved functional cure or discontinued NA therapy
+3 more records
Product overview1 text field

Arbutus Biopharma is a clinical-stage biopharmaceutical company developing a portfolio of therapeutics for chronic hepatitis B virus (HBV) infection. The company's product strategy centers on a three-pronged Suppress, Reduce, Boost approach using combination regimens: Imdusiran (AB-729), an RNAi therapeutic that reduces viral antigens including HBsAg; AB-101, an oral PD-L1 inhibitor designed to reawaken the host immune response; combined with nucleos(t)ide analogue therapy and immunotherapeutics. The company is conducting multiple Phase 2 clinical trials (IM-PROVE I and IM-PROVE II) evaluating these assets in combination regimens aimed at achieving functional cure in chronic hepatitis B patients.

Product and service1 record
1Imdusiran (AB-729)
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-04-01
Description

Arbutus licensed exclusive rights to its LNP and ligand conjugate delivery platforms to Genevant for RNA-based applications outside of HBV (except where rights already licensed to third parties). Arbutus retains all HBV rights. Arbutus owns approximately 16% of Genevant common equity and receives tiered low single-digit royalties on future product sales and 20% of sublicensing revenue.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

License agreement providing Arbutus royalty entitlements to Alnylam's global net sales of ONPATTRO (first FDA-approved application of Arbutus' LNP technology). Arbutus sold future royalty interest to OMERS but retains second lower royalty from Acuitas settlement.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaboration to evaluate AB-729 (imdusiran) in combination with Barinthus' proprietary immunotherapeutic VTP-300 in nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic HBV. Ongoing in IM-PROVE II trial.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China/US clinical-stage company developing combination therapies for HBV functional cure, including siRNA assets and immunotherapeutics, with overlapping patient population and combination-regimen strategy similar to Arbutus.

TypeBroad incumbent
Description

Established antisense oligonucleotide (RNA-targeted) therapeutics company with multiple commercial and clinical-stage assets; comparable in RNA-based therapeutic modality targeting liver and other diseases.

TypeDirect peer
Description

Clinical-stage RNAi therapeutics company with multiple GalNAc-conjugated siRNA programs targeting liver diseases; directly comparable platform technology to Arbutus' GalNAc-siRNA delivery system.

TypeBroad incumbent
Description

Major pharmaceutical company with established HBV franchise (Pegasys/pegylated interferon) and ongoing HBV cure research; overlapping HBV therapeutic space but operating as a broad incumbent rather than HBV-focused specialist.

TypeBroad incumbent
Description

Commercial-stage leader in RNAi therapeutics (Onpattro, Givlaari) and Arbutus' LNP licensee; comparable platform technology and a broader commercial RNAi franchise spanning multiple indications.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company developing siRNA and antisense oligonucleotide therapies for liver and neurological indications; platform-level overlap with Arbutus but earlier stage.

TypeDirect peer
Description

Clinical-stage immunotherapy company whose VTP-300 immunotherapeutic is being combined with Arbutus' imdusiran in the IM-PROVE II trial; directly comparable HBV cure approach and active clinical collaborator.

TypeDirect peer
Description

Clinical-stage immunology company developing VIR-2218, an siRNA therapeutic for chronic hepatitis B, directly competing with Arbutus' imdusiran on the same antigen-reduction mechanism and same HBV patient population.

TypeEmerging player
Description

Clinical-stage RNA medicines company developing both siRNA and mRNA therapeutics with proprietary LNP delivery; partial overlap with Arbutus on RNA delivery platforms and HBV-adjacent liver disease programs.

TypeBroad incumbent
Description

Market leader in chronic hepatitis B antivirals (Vemlidy) and a major participant in HBV cure research through partnerships and internal programs; overlapping patient population but established commercial franchise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arbutus Biopharma

Hepatitis B Therapeuticsarbutusbio.com

Arbutus Biopharma is a clinical-stage biopharmaceutical company developing RNAi and oral PD-L1 combination therapies to achieve a functional cure for chronic hepatitis B, monetizing its GalNAc-siRNA and lipid nanoparticle platforms through licensing, royalties, and patent litigation settlements.

What Arbutus Biopharma does

Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company developing a combination therapeutic regimen to achieve a functional cure for chronic hepatitis B virus (HBV) infection. The company's pipeline is built around a three-pronged "Suppress, Reduce, Boost" strategy combining nucleos(t)ide analogues with its proprietary assets: imdusiran (AB-729), a subcutaneously-delivered GalNAc-conjugated RNAi therapeutic designed to reduce all HBV viral antigens including HBsAg; and AB-101, an oral small-molecule PD-L1 checkpoint inhibitor intended to reinvigorate the host immune response. Imdusiran received FDA Fast Track designation in April 2026 and has demonstrated functional cure in 46% of Phase 2a patients in the IM-PROVE I trial.

The company monetizes its technology through a mix of licensing royalties, milestone payments, and patent litigation proceeds rather than product sales. Its lipid nanoparticle (LNP) delivery platform — foundational to the first FDA-approved siRNA therapeutic ONPATTRO — is licensed to Genevant Sciences (in which Arbutus holds ~16% equity) and Alnylam Pharmaceuticals. A landmark $2.25 billion global settlement with Moderna in March 2026 ($950M upfront plus up to $1.3B contingent on appellate ruling) and a separate ~$190M settlement with Pfizer/BioNTech validate the LNP patent estate. Arbutus also collaborates with Barinthus Biotherapeutics on the IM-PROVE II combination trial. The company is headquartered in Warminster, Pennsylvania, employs 51–100 people, and operates with a leadership team installed in 2025 (CEO Lindsay Androski, CFO Tuan Nguyen, GC Andrew Sung); Roivant Sciences remains its largest shareholder with two board seats.

Arbutus Biopharma firmographics

Firmographics
Name
Arbutus Biopharma
Legal name
Arbutus Biopharma Corporation
Website
https://arbutusbio.com
Company type
Public
Founded year
1992
Operating status
Operating
Headcount range
11–50 employees
Short description
Arbutus Biopharma is a clinical-stage biopharmaceutical company developing RNAi and oral PD-L1 combination therapies to achieve a functional cure for chronic hepatitis B, monetizing its GalNAc-siRNA and lipid nanoparticle platforms through licensing, royalties, and patent litigation settlements.
Ownership category
akta.pro rank

Arbutus Biopharma industry classification

Industry
Product category
Hepatitis B Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNAi therapeutics
  • Hepatitis B treatments
  • Biopharmaceutical development
  • Clinical-stage biotechnology
  • Viral disease therapeutics

Where Arbutus Biopharma is headquartered

Location

Headquarters

HQ city
Warminster
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Arbutus Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing Royalties: Tiered low single-digit royalties on future sales of Genevant products covered by licensed LNP patents. If Genevant sub-licenses, Arbutus receives lesser of 20% of sublicensing revenue or tiered low single-digit royalties. Arbutus owns approximately 16% of Genevant common equity.
  2. Settlement Revenue: One-time settlement payments from patent litigation. Q1 2026 estimated license revenue of $178.7M from $950M Moderna settlement (July 2026 payment). Additional $1.3B contingent on appellate ruling. Separate $190M from Pfizer/BioNTech settlement.
  3. ONPATTRO Royalties: Tiered royalty payments on global net sales of ONPATTRO (first FDA-approved application of Arbutus' LNP technology by Alnylam). Arbutus sold royalty interest on future global net sales to OMERS but retains second lower royalty from Acuitas settlement.
  4. Milestone Payments: Potential milestone payment from Alnylam for a product targeting hepatocellular carcinoma, as referenced in Q4 2025 results.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Arbutus Biopharma product offering

Product offering

Core offering

Arbutus Biopharma is a clinical-stage biopharmaceutical company developing a portfolio of therapeutics to achieve a functional cure for chronic hepatitis B (HBV) infection. The company's lead asset, imdusiran (AB-729), is a subcutaneously delivered GalNAc-conjugated RNA interference (RNAi) therapeutic that reduces HBV viral antigens including HBsAg. Its second clinical asset, AB-101, is an oral small-molecule PD-L1 inhibitor designed to reinvigorate the host immune response. Combination regimens including imdusiran, AB-101, nucleos(t)ide analogues, and immunotherapeutics are being evaluated in Phase 2 clinical trials under the company's three-pronged Suppress, Reduce, Boost approach.

Product overview

Arbutus Biopharma is a clinical-stage biopharmaceutical company developing a portfolio of therapeutics for chronic hepatitis B virus (HBV) infection. The company's product strategy centers on a three-pronged Suppress, Reduce, Boost approach using combination regimens: Imdusiran (AB-729), an RNAi therapeutic that reduces viral antigens including HBsAg; AB-101, an oral PD-L1 inhibitor designed to reawaken the host immune response; combined with nucleos(t)ide analogue therapy and immunotherapeutics. The company is conducting multiple Phase 2 clinical trials (IM-PROVE I and IM-PROVE II) evaluating these assets in combination regimens aimed at achieving functional cure in chronic hepatitis B patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Imdusiran (AB-729)

Quantifiable outcome

  • 46% of Phase 2a patients achieved functional cure or discontinued NA therapy
  • +3 more outcomes

Companies that use Arbutus Biopharma

Customer profile

Segments1 record

Ideal customer profiles2 records

Arbutus Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Arbutus Biopharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Genevant Sciences LtdcoreOEM/ Whitelabel/ Licensing Partner · 1 April 2018Arbutus licensed exclusive rights to its LNP and ligand conjugate delivery platforms to Genevant for RNA-based applications outside of HBV (except where rights already licensed to third parties). Arbutus retains all HBV rights. Arbutus owns approximately 16% of Genevant common equity and receives tiered low single-digit royalties on future product sales and 20% of sublicensing revenue.
  • Alnylam Pharmaceuticals, Inc.coreOEM/ Whitelabel/ Licensing PartnerLicense agreement providing Arbutus royalty entitlements to Alnylam's global net sales of ONPATTRO (first FDA-approved application of Arbutus' LNP technology). Arbutus sold future royalty interest to OMERS but retains second lower royalty from Acuitas settlement.
  • Barinthus Biotherapeutics plccoreStrategic or Co-development PartnerClinical collaboration to evaluate AB-729 (imdusiran) in combination with Barinthus' proprietary immunotherapeutic VTP-300 in nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic HBV. Ongoing in IM-PROVE II trial.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Arbutus Biopharma competitors and assessment

Company assessment

Direct peers

  • Brii Biosciences: China/US clinical-stage company developing combination therapies for HBV functional cure, including siRNA assets and immunotherapeutics, with overlapping patient population and combination-regimen strategy similar to Arbutus.
  • Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with multiple GalNAc-conjugated siRNA programs targeting liver diseases; directly comparable platform technology to Arbutus' GalNAc-siRNA delivery system.
  • Barinthus Biotherapeutics: Clinical-stage immunotherapy company whose VTP-300 immunotherapeutic is being combined with Arbutus' imdusiran in the IM-PROVE II trial; directly comparable HBV cure approach and active clinical collaborator.
  • Vir Biotechnology: Clinical-stage immunology company developing VIR-2218, an siRNA therapeutic for chronic hepatitis B, directly competing with Arbutus' imdusiran on the same antigen-reduction mechanism and same HBV patient population.

Broad incumbents

  • Ionis Pharmaceuticals: Established antisense oligonucleotide (RNA-targeted) therapeutics company with multiple commercial and clinical-stage assets; comparable in RNA-based therapeutic modality targeting liver and other diseases.
  • Roche: Major pharmaceutical company with established HBV franchise (Pegasys/pegylated interferon) and ongoing HBV cure research; overlapping HBV therapeutic space but operating as a broad incumbent rather than HBV-focused specialist.
  • Alnylam Pharmaceuticals: Commercial-stage leader in RNAi therapeutics (Onpattro, Givlaari) and Arbutus' LNP licensee; comparable platform technology and a broader commercial RNAi franchise spanning multiple indications.
  • Gilead Sciences: Market leader in chronic hepatitis B antivirals (Vemlidy) and a major participant in HBV cure research through partnerships and internal programs; overlapping patient population but established commercial franchise.

Emerging players

  • Wave Life Sciences: Clinical-stage RNA therapeutics company developing siRNA and antisense oligonucleotide therapies for liver and neurological indications; platform-level overlap with Arbutus but earlier stage.
  • Arcturus Therapeutics: Clinical-stage RNA medicines company developing both siRNA and mRNA therapeutics with proprietary LNP delivery; partial overlap with Arbutus on RNA delivery platforms and HBV-adjacent liver disease programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Arbutus Biopharma social profiles

Digital presence

Arbutus Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arbutus Biopharma leadership team

Management profile

Number of profiles

Profiles7 records

Arbutus Biopharma funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arbutus Biopharma M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arbutus Biopharma

What does Arbutus Biopharma do?

Arbutus Biopharma is a clinical-stage biopharmaceutical company developing a portfolio of therapeutics to achieve a functional cure for chronic hepatitis B (HBV) infection. The company's lead asset, imdusiran (AB-729), is a subcutaneously delivered GalNAc-conjugated RNA interference (RNAi) therapeutic that reduces HBV viral antigens including HBsAg. Its second clinical asset, AB-101, is an oral small-molecule PD-L1 inhibitor designed to reinvigorate the host immune response. Combination regimens including imdusiran, AB-101, nucleos(t)ide analogues, and immunotherapeutics are being evaluated in Phase 2 clinical trials under the company's three-pronged Suppress, Reduce, Boost approach.

Is Arbutus Biopharma a public or private company?

Arbutus Biopharma is a public company. It is classified as public and is currently operating.

When was Arbutus Biopharma founded?

Arbutus Biopharma was founded in 1992. It employs 11 to 50 people.

Where is Arbutus Biopharma based?

Arbutus Biopharma is headquartered in Warminster, United States, in the North America region.

How does Arbutus Biopharma make money?

Four revenue lines are on record. Licensing Royalties are the primary driver. The others are settlement Revenue, ONPATTRO Royalties and milestone Payments.

Who are Arbutus Biopharma's main competitors?

Direct peers on record are Brii Biosciences, Arrowhead Pharmaceuticals, Barinthus Biotherapeutics and Vir Biotechnology. Broad incumbents are Ionis Pharmaceuticals, Roche, Alnylam Pharmaceuticals and Gilead Sciences. Emerging players are Wave Life Sciences and Arcturus Therapeutics.

Does Arbutus Biopharma have an API?

No public API is recorded for Arbutus Biopharma.

What industry is Arbutus Biopharma in?

Arbutus Biopharma's product category is Hepatitis B Therapeutics. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsArbutus Biopharma Corporation $ABUS Stock Sold by CenterBook Partners LPCenterBook Partners LP reduced its stake in Arbutus Biopharma by 72.1% in Q3, selling 321,037 shares and holding 124,114 shares worth $593,000. Other institutional investors also bought or sold shares, and the stock opened at $3.88. The company reported Q3 EPS of $0.30, beating estimates, and initiated a stock buyback.MarketScreenerArbutus Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Arbutus Biopharma reported Q3 and nine-month earnings for the period ended September 30, 2026. Revenue rose to $180.44 million from $13.03 million a year earlier, and net income turned to $223.67 million from a $29.75 million loss. Basic EPS was $1.14 versus a $0.16 loss.Seeking AlphaArbutus Biopharma GAAP EPS of $0.30 beats by $0.32, revenue of $0.3M misses by $0.7MArbutus Biopharma reported Q3 GAAP EPS of $0.30, beating estimates by $0.32, while revenue of $0.3 million missed by $0.7 million. As of September 30, 2026, the company held $337.5 million in cash and investments, up from $91.5 million a year earlier.American Banking and Market NewsPliant Therapeutics (NASDAQ:PLRX) versus Arbutus Biopharma (NASDAQ:ABUS) Head-To-Head ComparisonA head-to-head comparison of Arbutus Biopharma and Pliant Therapeutics evaluates their ratings, risk, ownership, and profitability. Arbutus beats Pliant on 9 of 12 factors, with higher revenue and earnings, while Pliant shows higher analyst upside. Pliant's beta is 1.36 versus Arbutus's 0.84.Investing.comWhy is Arbutus Biopharma stock climbing today?Arbutus Biopharma's stock rose 5.3% pre-open after the FDA removed the clinical hold on AB-101, its oral PD-L1 inhibitor for chronic hepatitis B. The drug had completed a Phase 1a/1b trial showing high receptor occupancy, and the move clears U.S. trial enrollment. Assenagon Asset Management initiated a new position of over 620,000 shares.TradingViewArbutus Biopharma Clears FDA Clinical Hold on AB-101 INDThe FDA lifted the clinical hold on Arbutus Biopharma's AB-101 IND, allowing further U.S. clinical development of its oral PD-L1 inhibitor. The drug completed a Phase 1a/1b trial in healthy subjects and chronic HBV patients, showing it was generally well-tolerated with high receptor occupancy and some HBsAg declines at 30 mg.MarketBeat620,717 Shares in Arbutus Biopharma Corporation $ABUS Acquired by Assenagon Asset Management S.A.Assenagon Asset Management acquired a new stake in Arbutus Biopharma, purchasing 620,717 shares worth about $2.97 million in Q3. The firm now holds 0.31% of the company, while institutional investors own 43.79% of the stock. Analysts rate the stock a Moderate Buy with a $5.00 price target.Ticker ReportReviewing Arbutus Biopharma (NASDAQ:ABUS) & Prelude Therapeutics (NASDAQ:PRLD)A comparison of Arbutus Biopharma and Prelude Therapeutics shows Arbutus has higher profitability and institutional ownership, while Prelude has a lower beta and higher analyst upside. Arbutus beats Prelude on 8 of 14 factors, with analysts favoring Prelude due to its lower valuation and higher potential upside.MarketBeatArbutus Biopharma Corporation (NASDAQ:ABUS) Stock Short Interest Rises 84.2%Arbutus Biopharma's short interest rose 84.2% to 34.05 million shares as of September 30, with 21.5% of shares sold short. The company reported a quarterly loss of $0.03 per share, missing estimates, and declared a $0.00 buyback plan. Analysts rate the stock a Moderate Buy with a $5.00 price target.American Banking and Market NewsArbutus Biopharma (NASDAQ:ABUS) & Syndax Pharmaceuticals (NASDAQ:SNDX) Head-To-Head ComparisonArbutus Biopharma and Syndax Pharmaceuticals are compared on financials, analyst ratings, and ownership. Syndax has a stronger consensus rating and higher upside, while Arbutus beats on 10 of 14 factors. Analysts see Syndax as more favorable.